iBio Announces Proposed Public Offering

Core Viewpoint - iBio, Inc. has initiated an underwritten public offering of pre-funded warrants and Series G and H warrants to raise capital for advancing its preclinical cardiometabolic programs and other pipeline assets [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants to purchase shares of iBio's common stock and accompanying Series G and H warrants [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. - Leerink Partners is the lead bookrunning manager, with LifeSci Capital and Oppenheimer & Co. as bookrunning managers [3]. Group 2: Use of Proceeds - iBio plans to use the net proceeds from the offering to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, through key development milestones [2]. - Additional proceeds will be allocated to fund working capital requirements and other general corporate purposes [2]. Group 3: Regulatory Information - The offering is made under a shelf registration statement filed with the SEC, which became effective on August 6, 2024 [4]. - A preliminary prospectus supplement and accompanying base prospectus will be filed with the SEC and made available on their website [4].